Starboard Value, Parvus Asset Management, and Elliott Management collectively filed six 13D disclosure forms between April 14 and April 20, establishing positions in Smith & Nephew ($12.8B market cap), Autodesk ($58B), Accor (€9.1B), Orthofix Medical ($1.2B), and two undisclosed mid-cap industrials. The aggregate disclosed stake value exceeds $2.1B, and the targets span medical devices, enterprise software, European hospitality, and specialty manufacturing. None of the filings were pre-announced. All arrived within the same SEC Edgar batch window.

The pattern is velocity, not theme. Starboard took a 7.8% position in Smith & Nephew on April 15, citing undervaluation relative to peers and operational bloat in the orthopedics segment. Parvus filed on Orthofix the following day with 9.2% ownership and a stated intent to engage management on margin structure. Elliott's Autodesk stake—4.1%, filed April 18—arrived with a private letter already delivered to the board requesting a review of subscription pricing models and SG&A as a percentage of revenue. Accor's filing came from an undisclosed New York fund with $4.7B AUM, marking its first European hospitality position since 2019. The two remaining 13Ds are sub-$500M market cap names in adhesives and precision components, both based in the Midwest.

This is spring positioning ahead of the summer engagement blackout. Activists file 13Ds when they have board conversations scheduled or when they expect catalysts inside a 90-day window. The clustering suggests shared intelligence on M&A liquidity or upcoming earnings revisions. Smith & Nephew reports May 1. Autodesk's fiscal Q1 is May 23. Orthofix has a June 12 investor day already on the calendar. The Accor filing included a Schedule 13D Item 4 notation referencing "strategic alternatives discussions," which typically means asset sales or portfolio rationalization. The timing aligns with post-Easter liquidity in European credit markets and the end of Q1 cash-position reporting for U.S. corporates.

The activist playbook has shifted from hostile proxy fights to collaborative engagement with CFOs who already know their cost structure is indefensible. Starboard's Smith & Nephew letter—leaked to the Financial Times on April 19—proposed $340M in annual cost cuts by 2026, primarily through manufacturing footprint consolidation and a reduction in regional overlaps. Elliott's Autodesk engagement centers on 18% SG&A as a percentage of revenue versus 12% at Adobe and 14% at Salesforce. Parvus has a track record of forcing spin-offs in medical device conglomerates; Orthofix operates in both spine and orthopedics, a structure Parvus has publicly criticized in prior campaigns. The thesis is separation, not optimization.

Allocators should track three follow-on signals in the next 45 days. First, whether any of these activists file amended 13Ds raising their stakes above 10%, which typically precedes a public campaign. Second, proxy advisory firm ISS and Glass Lewis commentary on Smith & Nephew and Autodesk governance structures, expected late April. Third, credit spreads on Accor's €500M 2027 notes, currently trading at 112 bps over mid-swaps; any tightening below 100 bps would indicate that debt markets are pricing in asset sale proceeds ahead of official announcements.

The last time three named activists filed within a single week was October 2021, just before the Russell rebalance. Four of those five targets were acquired or taken private within 18 months.